Would the concerns about respiratory side effects from sodium phenylbutyrate and taurusodiol change your management of patients with predominantly bulbar ALS?
Answer from: at Community Practice
When you say "respiratory side effects" I assume you are referring to the rate of upper respiratory tract infections being higher in the Relyvrio-treated patients compared to the placebo-treated ones. I cannot think of a reason this product would make patients more susceptible to respiratory infecti...
Sign in or Register to read more
Answer from: at Academic Institution
I am not sure what respiratory side effects are intended, as no specific ones were included in the Paganoni et al., PMID 32877582 article. In clinic, I assess for respiratory symptoms and perform pulmonary function tests and treat all patients the same for respiratory involvement independent of site...
Answer from: at Community Practice
Side effects seen in the trial should be discussed. However, most people would agree that there is a favorable benefit/risk ratio in the context of ALS.